Profiles of m6A RNA methylation regulators for the prognosis of hepatocellular carcinoma

Li,Wang; Chen,Qi‑Feng; Huang,Tao; Shen,Lujun; Huang,Zi‑Lin; Wu,Peihong

doi:10.3892/ol.2020.11435

Profiles of m6A RNA methylation regulators for the prognosis of hepatocellular carcinoma

Authors:
- Wang Li
- Qi‑Feng Chen
- Tao Huang
- Lujun Shen
- Zi‑Lin Huang
- Peihong Wu
View Affiliations

Affiliations: Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China, Department of Medical Imaging and Interventional Radiology, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
Published online on: March 3, 2020 https://doi.org/10.3892/ol.2020.11435
Pages: 3296-3306
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

N6‑methyladenosine (m6A) RNA methylation, which is related to cancer initiation and progression, is dynamically regulated by the m6A RNA methylation regulators (including ‘writers’, ‘erasers’ and ‘readers’). However, the prognostic value of m6A RNA methylation regulators involved in hepatocellular carcinoma (HCC) carcinogenesis and progression remains to be elucidated. The aim of the present study was to determine the prognostic score in predicting the prognosis of HCC patients based on these regulators. In The Cancer Genome Atlas, most of the 13 major m6A RNA methylation regulators were found to be differentially expressed between HCC and normal samples (P<0.001). In addition, two subgroups (clusters 1/2) had also been identified by applying consensus clustering in the m6A RNA methylation regulators. As compared with the cluster 1 subgroup, the cluster 2 subgroup was correlated with a poorer prognosis, as shown by the Kaplan‑Meier method (P=6.197e‑4). A risk signature was constructed based on these findings using six m6A RNA methylation regulators, which could not only predict the clinicopathological features of HCCs, but also serve as an independent prognostic marker, as shown by Cox regression analysis (hazard ratio=1.219, 95% confidence interval: 1.143‑1.299; P<0.001). Data from the International Cancer Genome Consortium were used for external validation. In addition, gene set enrichment analysis identified several pathways that m6A RNA methylation regulators were closely associated with. In conclusion, the m6A RNA methylation regulators are the crucial participants in the malignant progression of HCCs, which are potentially useful for prognosis stratification and therapeutic strategy development for HCC.

View Figures

View References

1	He C: Grand challenge commentary: RNA epigenetics? Nat Chem Biol. 6:863–865. 2010. View Article : Google Scholar : PubMed/NCBI
2	Boccaletto P, Machnicka MA, Purta E, Piatkowski P, Baginski B, Wirecki TK, de Crécy-Lagard V, Ross R, Limbach PA, Kotter A, et al: MODOMICS: A database of RNA modification pathways. 2017 update. Nucleic Acids Res. 46:D303–D307. 2018. View Article : Google Scholar : PubMed/NCBI
3	Ji P, Wang X, Xie N and Li Y: N6-methyladenosine in RNA and DNA: An epitranscriptomic and epigenetic player implicated in determination of stem cell fate. Stem Cells Int. 2018:32565242018. View Article : Google Scholar : PubMed/NCBI
4	Chai RC, Wu F, Wang QX, Zhang S, Zhang KN, Liu YQ, Zhao Z, Jiang T, Wang YZ and Kang CS: m(6)A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas. Aging (Albany NY). 11:1204–1225. 2019. View Article : Google Scholar : PubMed/NCBI
5	Meyer KD and Jaffrey SR: Rethinking m(6)A readers, writers, and erasers. Annu Rev Cell Dev Biol. 33:319–342. 2017. View Article : Google Scholar : PubMed/NCBI
6	Roundtree IA and He C: RNA epigenetics-chemical messages for posttranscriptional gene regulation. Curr Opin Chem Biol. 30:46–51. 2016. View Article : Google Scholar : PubMed/NCBI
7	Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amariglio N, Kupiec M, et al: Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 485:201–206. 2012. View Article : Google Scholar : PubMed/NCBI
8	Li X, Xiong X and Yi C: Epitranscriptome sequencing technologies: Decoding RNA modifications. Nat Methods. 14:23–31. 2016. View Article : Google Scholar : PubMed/NCBI
9	Wang S, Sun C, Li J, Zhang E, Ma Z, Xu W, Li H, Qiu M, Xu Y, Xia W, et al: Roles of RNA methylation by means of N(6)-methyladenosine (m(6)A) in human cancers. Cancer Lett. 408:112–120. 2017. View Article : Google Scholar : PubMed/NCBI
10	Huang J and Yin P: Structural insights into N(6)-methyladenosine (m(6)A) modification in the transcriptome. Genomics Proteomics Bioinformatics. 16:85–98. 2018. View Article : Google Scholar : PubMed/NCBI
11	Luo J, Liu H, Luan S, He C and Li Z: Aberrant regulation of mRNA m(6)A modification in cancer development. Int J Mol Sci. 19:E25152018. View Article : Google Scholar : PubMed/NCBI
12	Deng X, Su R, Feng X, Wei M and Chen J: Role of N(6)-methyladenosine modification in cancer. Curr Opin Genet Dev. 48:1–7. 2018. View Article : Google Scholar : PubMed/NCBI
13	Chen QF, Jia ZY, Yang ZQ, Fan WL and Shi HB: Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-microwave ablation therapy for hepatocellular carcinoma tumors </=5 cm: A propensity analysis at a single center. Cardiovasc Intervent Radiol. 40:1748–1755. 2017. View Article : Google Scholar : PubMed/NCBI
14	Chen QF, Huang T, Shen L and Li W: Predictive value of a nomogram for hepatocellular carcinoma with brain metastasis at initial diagnosis: A population-based study. PLoS One. 14:e02092932019. View Article : Google Scholar : PubMed/NCBI
15	Chen QF, Li W, Wu P, Shen L and Huang ZL: Alternative splicing events are prognostic in hepatocellular carcinoma. Aging (Albany NY). 11:4720–4735. 2019.PubMed/NCBI
16	Chen QF, Li W, Wu PH, Shen LJ and Huang ZL: Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 25:5266–5282. 2019. View Article : Google Scholar : PubMed/NCBI
17	Friedman J, Hastie T and Tibshirani R: Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 33:1–22. 2010. View Article : Google Scholar : PubMed/NCBI
18	McNeish DM: Using lasso for predictor selection and to assuage overfitting: A method long overlooked in behavioral sciences. Multivariate Behav Res. 50:471–484. 2015. View Article : Google Scholar : PubMed/NCBI
19	Cheng X, Li M, Rao X, Zhang W, Li X, Wang L and Huang G: KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m6A modification of ID2 mRNA. OncoTargets Ther. 12:3421–3428. 2019. View Article : Google Scholar
20	Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, et al: RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 67:2254–2270. 2018. View Article : Google Scholar : PubMed/NCBI
21	Zhao X, Chen Y, Mao Q, Jiang X, Jiang W, Chen J, Xu W, Zhong L and Sun X: Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Biomark. 21:859–868. 2018. View Article : Google Scholar : PubMed/NCBI
22	Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, Wang TT, Xu QG, Zhou WP and Sun SH: METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N⁶ -methyladenosine-dependent primary MicroRNA processing. Hepatology. 65:529–543. 2017. View Article : Google Scholar : PubMed/NCBI
23	Yang Z, Li J, Feng G, Gao S, Wang Y, Zhang S, Liu Y, Ye L, Li Y and Zhang X: MicroRNA-145 modulates N⁶-methyladenosine levels by targeting the 3′-untranslated mRNA Region of the N⁶-methyladenosine binding YTH domain family 2 protein. J Biol Chem. 292:3614–3623. 2017. View Article : Google Scholar : PubMed/NCBI
24	Zhou Y, Yin Z, Hou B, Yu M, Chen R, Jin H and Jian Z: Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: Evidence from independent datasets. Cancer Manag Res. 11:3921–3931. 2019. View Article : Google Scholar : PubMed/NCBI
25	Pan Y, Ma P, Liu Y, Li W and Shu Y: Multiple functions of m⁶A RNA methylation in cancer. J Hematol Oncol. 11:482018. View Article : Google Scholar : PubMed/NCBI
26	Cui Q, Shi H, Ye P, Li L, Qu Q, Sun G, Sun G, Lu Z, Huang Y, Yang CG, et al: m⁶A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep. 18:2622–2634. 2017. View Article : Google Scholar : PubMed/NCBI
27	Dai D, Wang H, Zhu L, Jin H and Wang X: N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis. 9:1242018. View Article : Google Scholar : PubMed/NCBI
28	Xiang Y, Laurent B, Hsu CH, Nachtergaele S, Lu Z, Sheng W, Xu C, Chen H, Ouyang J, Wang S, et al: RNA m⁶A methylation regulates the ultraviolet-induced DNA damage response. Nature. 543:573–576. 2017. View Article : Google Scholar : PubMed/NCBI
29	Gao SB, Li KL, Qiu H, Zhu LY, Pan CB, Zhao Y, Wei SH, Shi S, Jin GH and Xue LX: Enhancing chemotherapy sensitivity by targeting PcG via the ATM/p53 pathway. Am J Cancer Res. 7:1874–1883. 2017.PubMed/NCBI
30	Meng YM, Liang J, Wu C, Xu J, Zeng DN, Yu XJ, Ning H, Xu L and Zheng L: Monocytes/Macrophages promote vascular CXCR4 expression via the ERK pathway in hepatocellular carcinoma. Oncoimmunology. 7:e14087452017. View Article : Google Scholar : PubMed/NCBI
31	Cheng Y, Li H, Deng Y, Tai Y, Zeng K, Zhang Y, Liu W, Zhang Q and Yang Y: Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis. 9:4222018. View Article : Google Scholar : PubMed/NCBI
32	Zhong L, Liao D, Zhang M, Zeng C, Li X, Zhang R, Ma H and Kang T: YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett. 442:252–261. 2019. View Article : Google Scholar : PubMed/NCBI